Advice
in the absence of a submission from the holder of the marketing authorisation:
imiquimod (Zyclara®) is not recommended for use within NHS Scotland.
Indication under review: topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Medicine details
- Medicine name:
- imiquimod (Zyclara)
- SMC ID:
- 934/13
- Indication:
- Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis (AK) of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.
- Pharmaceutical company
- Meda Pharmaceuticals Ltd
- BNF chapter
- Skin
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 09 December 2013